Osteopathy and Latent Hypothyroidism

Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02430857

Enrollment

Registered

2015-04-30

Start date

2015-10-31

Completion date

2016-01-31

Last updated

2015-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Hypothyroidism

Brief summary

This study evaluates the effectiveness of stimulating the neurological segments c8-th5 in patients with latent hypothyroidism. One half of the participants will receive an osteopathic manuel treatment in order to stimulate the relevant segments, the other half will receive no treatment.

Detailed description

Patients with latent hypothyroidism show an increased hormone status in TSH and a normal hormone status in fT4. A study has shown that osteopathic treatment had positive effects to some symptoms in patients with latent hypothyroidism. The study was using the pain inventory as the instrument to measure the effect. In this study we want to evaluate the effectiveness of the treatment on the hormone status (TSH, fT4) The intervention group will receive a neurological osteopathic stimulation over 5 weeks. A parallel control group will not receive any therapy. A follow up blood screening (TSH, fT4) will be done. The results of both groups will be compared.

Interventions

OTHEROMT

Manuel osteopathic treatment of the spine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* latent hypothyroidism

Exclusion criteria

* Factors that Alter Thyroxine and Triiodothyronine Binding in Serum * Increased thyroxin-binding globulin * Decreased thyroxin-binding globulin * Binding inhibitors * Inherited Salicylates * Pregnancy * Androgens * Furosemide * Neonatal state * Anabolic steroids * Free fatty acids * Estrogens * Glucocorticoids * Phenytoin * Hepatitis * Severe illness * Carbamazepine * Porphyria * Hepatic failure * nonsteroidal antiinflammatory drug (variable, transient) * Heroin * Nephrosis * Heparin * Methadone * Nicotinic acid * Mitotane L-Asparaginase * 5-Fluorouracil * SERMS (e.g., tamoxifen, raloxifene) * Perphenazine * spinal pathologies

Design outcomes

Primary

Measure	Time frame
Change in TSH Concentration	5 weeks

Contacts

Primary ContactEmanuel Diekmann, DO

Emanuel.diekmann@gmx.de0041788800341

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026